---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061122"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T12:27:12.152126+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q3 net sales $184M (+61% reported, +8% pro forma); GAAP EPS -$0.77, adj. $0.07

## Summary
- Net sales $184M, +61% reported, +8% pro forma (excl. one-time stocking order); Bone Growth Therapies +15%.
- GAAP net loss $28.9M ($0.77/share); adjusted net income $2.7M ($0.07/share); adjusted EBITDA $13.5M (7.3% of sales).
- Entered new $150M financing agreement (Nov 6, 2023), replaced prior $175M revolver; cash $33.7M at Sep 30.
- Updated 2023 net sales guidance lowered to $739M-$744M (prev $752M-$758M); adjusted EBITDA guidance unchanged $42M-$46M.
- Management transition: Catherine Burzik (Chair) as Interim CEO after board investigation led to departure of three former executives.

## SEC filing metadata
- accession: 0000950170-23-061122
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/0000950170-23-061122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/ofix-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061122
- JSON: https://secwatch.observer/filing/0000950170-23-061122.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061122.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported the quarter ended September 30, 2023 results: revenue $184.0 million, net income Net loss was $(28.9) million, EPS $(0.77). Guidance reaffirmed.
  - Period: the quarter ended September 30, 2023
  - Revenue: $184.0 million
  - Net income: Net loss was $(28.9) million
  - EPS: $(0.77)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net sales were $184.0 million, earnings per share (“EPS”) was $(0.77), and adjusted EPS was $0.07.
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/0000950170-23-061122-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.